






Physician: Sample Practitioner, MD  
 Patient: Sample Patient  
 Identifier: SAMPLE176  
 Profile: MRT 176  
 Test Date: 02/28/2023  
 Technologist: GB  
 Page: 1 of 2








Oxford Biomedical Technologies  
 3555 Fiscal Court, Suite #9  
 Riviera Beach, FL 33404  
 Phone: (561) 848-7111  
 FL License #: 800027063  
 CLIA ID #: 10D0914874  
 U.S. Patents: 6,114,174 6,200,815



Physician: Sample Practitioner, MD  
 Patient: Sample Patient  
 Identifier: SAMPLE176  
 Profile: MRT 176  
 Test Date: 02/28/2023  
 Technologist: GB  
 Page: 2 of 2



Oxford Biomedical Technologies  
 3555 Fiscal Court, Suite #9  
 Riviera Beach, FL 33404  
 Phone: (561) 848-7111  
 FL License #: 800027063  
 CLIA ID #: 10D0914874  
 U.S. Patents: 6,114,174 6,200,815



**Interpretation:** The Leukocyte Activation Assay-Mediator Release Test™ (LAA-MRT™) results are based on the Leukocyte Reactivity Index (LRI™), a proprietary algorithm developed by Oxford Biomedical Technologies. The LRI™ quantifies the relative degree of volumetric change of tested peripheral leukocytes and is a reflection of the degree of the inflammatory response to each tested item. LAA-MRT™ test results form the basis of an anti-inflammatory eating plan developed under the guidance of a qualified healthcare practitioner.

**Disclaimer:** It is recommended to completely avoid all tested items with Moderate or High reaction levels. Reintroduction of items that tested Moderate or High should be done under the supervision of a properly trained healthcare practitioner. If foods and chemicals that tested Low have been consumed regularly before testing, there is a high probability that they are not likely to provoke inflammatory symptoms, as long as there is no history of allergic, autoimmune, or other forms of inflammation-provoking or symptom-provoking reaction.